Ibiron

Abiraterone acetate, the active ingredient in Ibiron, is an androgen biosynthesis inhibitor presented as an oral tablet for oral use. It treats metastatic castration‑resistant prostate cancer in men who have progressed despite androgen deprivation therapy.

GNH USA supplies Ibiron as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Ibiron is an androgen biosynthesis inhibitor used in the management of prostate cancer that has become resistant to standard hormonal therapy. - Metastatic castration‑resistant prostate cancer: improves overall survival and delays disease progression when combined with prednisone. - Castration‑resistant prostate cancer: reduces tumor growth by lowering systemic and intratumoral androgen levels. - Advanced prostate cancer: used after progression on androgen deprivation therapy to extend clinical benefit.

Ibiron may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Hypertension: elevated blood pressure requiring monitoring. - Nausea: mild to moderate gastrointestinal upset. - Edema: swelling of extremities due to fluid retention. - Hot flashes: transient episodes of warmth and sweating.

Serious or Rare Side Effects: - Liver enzyme elevation: potential hepatotoxicity needing periodic liver function tests. - Adrenal insufficiency: reduced cortisol production that may cause fatigue and hypotension. - Severe hypertension or cardiac failure: may require medical intervention. - Thromboembolic events: rare blood clot formation. - Interstitial lung disease: uncommon respiratory complications.

Before initiating Ibiron, clinicians should assess patient-specific risk factors and monitor relevant parameters. - Monitor blood pressure: check regularly to detect hypertension. - Monitor potassium and electrolyte levels: watch for hypokalemia and fluid imbalance. - Assess liver function: perform baseline and periodic liver enzyme tests. - Avoid concomitant strong CYP3A4 inducers: may reduce drug efficacy. - Use with low‑dose prednisone: mitigates mineralocorticoid‑related side effects. - Store at ambient temperature: keep in the original pack, protect from moisture.

Ibiron can interact with several medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly decrease abiraterone exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can increase drug levels and toxicity. - Mineralocorticoid agonists (e.g., fludrocortisone): may exacerbate fluid retention and hypertension.

Moderate Interactions (Monitor Closely):\n- Antihypertensive agents: may require dose adjustments due to blood‑pressure changes. - Anticoagulants: monitor for altered bleeding risk. - CYP2D6 substrates: observe for potential pharmacokinetic alterations.